AIM: To assess the immunogenicity of hepatitis B vaccine in preterm and term infants, given in a sequence of three doses beginning soon after birth. METHOD: The immunogenicity of hepatitis B vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after birth, and compared with that in 46 term infants. Titres of hepatitis B antibodies were determined one to two months after the third vaccine. The significance of the differences between the term and preterm groups was determined using Student's t test. RESULTS: A similar proportion of infants in both preterm and term groups attained protective titres of hepatitis B antibodies (88.7% vs 93.4%, respectively; p = NS). However, the term infants had a higher geometric mean titre of antibodies after the third vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p < 0.03). CONCLUSION: Hepatitis B vaccine is effective in most preterm infants when given soon after birth. It may be advisable to determine the immune response at 12-24 months of age to booster the non-responders.
AIM: To assess the immunogenicity of hepatitis B vaccine in preterm and term infants, given in a sequence of three doses beginning soon after birth. METHOD: The immunogenicity of hepatitis B vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after birth, and compared with that in 46 term infants. Titres of hepatitis B antibodies were determined one to two months after the third vaccine. The significance of the differences between the term and preterm groups was determined using Student's t test. RESULTS: A similar proportion of infants in both preterm and term groups attained protective titres of hepatitis B antibodies (88.7% vs 93.4%, respectively; p = NS). However, the term infants had a higher geometric mean titre of antibodies after the third vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p < 0.03). CONCLUSION:Hepatitis B vaccine is effective in most preterm infants when given soon after birth. It may be advisable to determine the immune response at 12-24 months of age to booster the non-responders.
Authors: C A Alper; M S Kruskall; D Marcus-Bagley; D E Craven; A J Katz; S J Brink; J L Dienstag; Z Awdeh; E J Yunis Journal: N Engl J Med Date: 1989-09-14 Impact factor: 91.245
Authors: N Linder; M Yaron; R Handsher; J Kuint; E Birenbaum; R Mazkereth; D Lubin; E Mendelson; O Safrir; B Reichman Journal: J Pediatr Date: 1995-07 Impact factor: 4.406
Authors: S Sanpavat; Y Poovorawan; S Chittinand; S Bhongsvej; P Thaithumyanon Journal: Southeast Asian J Trop Med Public Health Date: 1994-03 Impact factor: 0.267
Authors: P T Heath; R Booy; J McVernon; J Bowen-Morris; H Griffiths; M P E Slack; A C Moloney; M E Ramsay; E R Moxon Journal: Arch Dis Child Date: 2003-03 Impact factor: 3.791